Latigo Biotherapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-17. It has amended it 2 times. It filed its final prospectus on 2026-08-07, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “LTGO”.From the 424B4 filed 2026-08-07
Shares offered
This is an initial public offering of shares of common stock of Latigo Biotherapeutics, Inc. We are offering 19,200,000 shares of our common stock to be sold in this offering.From the 424B4 filed 2026-08-07
Offering price
The initial public offering price is $18.00 per share.From the 424B4 filed 2026-08-07
Use of proceeds
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, (i) to advance the development of LTG-001 through Phase 3 bunionectomy and open-label safety topline results and to NDA submission, as well as commercial readiness, (ii) to advance the development of LTG-321 through Phase 2 osteoarthritis pain proof of concept topline results and the start of Phase 3 clinical development, and (iii) for other research and development activities, including the development of LTG-418, as well as for working capital and other general corporate purposes.From the 424B4 filed 2026-08-07
Net loss or income
For the years ended December 31, 2024 and 2025, our net losses were approximately $61.2 million and $109.2 million, respectively, and our accumulated deficit as of March 31, 2026 was approximately $266.1 million.From the S-1/A filed 2026-08-04
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-07-17 | Registration statement filed | S-1 |
| 2026-08-03 | Registration statement amended | S-1/A |
| 2026-08-04 | Registration statement amended | S-1/A |
| 2026-08-07 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Latigo Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.